--- Query Results --- | |||||
| Organization: | Alberta Precision Laboratories | ||||
| Message Alert: | PLEASE NOTE: This Test Directory is in an interim state and due to changes pertaining to the DynaLIFE transition, performing site for routing has not been updated. Please refer to Laboratory Information System for appropriate routing. | ||||
| Test Name/Synonym: | Tumour Cell Free DNA NGS Testing (Referred Test) (Synonym: liquid biopsy, prostate cancer, lung cancer, circulating turmor DNA (ctDNA) prostate testing) | ||||
| Clinical Indications: | For investigation of metastatic and castration-resistant prostate cancer as well as lung cancers. | ||||
| Collection Alert: | Unopened dedicated tubes are required for molecular testing. Restricted collection locations: see specimen collection requirements. | ||||
| Shipping and Handling Alert: | Transport specimens to designated Hub lab locations (Calgary: DSC, Edmonton: UAH). Requests will be reviewed by the Edmonton Molecular Pathology lab and if approved, the Hub labs will refer specimens to Foothills Medical Centre, McCaig Tower, 7th floor, who will then forward to OncoHelix/HTL. Time sensitive: specimen must be received by OncoHelix/HTL within 7 days of collection. | ||||
| LABID (Connect Care): | LAB9486 | ||||
| Specimen Type: | Blood | ||||
| Specimen Source: | Blood | ||||
| Primary Container: | 10 mL black and brown top - STRECK Cell-Free DNA BCT® (blood collection tube) and 5 mL Lavendar EDTA collection tube (EDTA tube is only required for prostate cancer requests) | ||||
| Minimum Collection Volume: | STRECK: 20.0 mL EDTA: 5.0 mL (EDTA tube is only required for prostate cancer requests) | ||||
| Specimen Collection Requirements: | Collect two full STRECK Cell-Free DNA blood collection tubes and also collect one full lavendar EDTA blood collection tube (EDTA tube is only required for prostate cancer requests). When using a winged blood collection set (butterfly needle) a discard tube must be used if only a Streck Cell-Free DNA blood collection tube is drawn or is the first tube drawn. Order of draw: after the EDTA tube and before the fluoride oxalate tube. Each tube must be full. Collection can only occur at one of the following collection sites:
| ||||
| Test Resources: | Submit request using appropriate OncoHelix requisition: Prostate cancer requisition:
Lung cancer requisition:
Please ensure all required information, including patient's clinical history/indication, is provided on the requisition. | ||||
| Stability and Storage: | Stable at room temperature. Specimen must be received by OncoHelix/HTL witin 7 days of collection. | ||||
| Processing: | Transport specimens to designated Hub lab locations (Calgary: DSC, Edmonton: UAH). Requests will be reviewed by the Edmonton Molecular Pathology lab and if approved, the Hub labs will refer specimens to Foothills Medical Centre, McCaig Tower, 7th floor, who will then forward to OncoHelix/HTL. Do not centrifuge. Do not aliquot. Do not refrigerate or freeze. Keep specimens at room temperature until ready to transport. | ||||
| Transportation: | Calgary and South zones: transport specimens at room temperature to DSC External Sendout department for processing and shipment to OncoHelix/HTL. Edmonton, Central and North zones: transport specimens at room temperature to UAH hub lab for processing and shipment to OncoHelix/HTL. | ||||
| Method: | Next-Generation Sequencing (NGS) | ||||
| Method and Interpretation of Results: | Liquid Biopsy ctDNA CGP Assay. SNVs & Indels: 146 genes CNV: 38 genes Fusions: 10 genes Promoter: 1 gene SNV and Indels as well as Copy Number Variation (amplification and deletion): APC, AR, ARID1A, ASXL1, ATM, BAP1, BRCA1, BRCA2, CDK12, CDK4, CDKN2A, CHEK2, DNMT3A, ERCC2, FBXW7, FOXL2, GATA3, HIST1H3B, KDM6A, KEAP1, KRAS, MLH1, MSH2, MSH6, NFI, PALB2, PMS2, PPM1D,, PTCH1, PTEN, RB1, SMAD4, STK11, TET2, TP53, TSC1, TSC2 and VHL. SNV and Indels as well as Fusions: ALK, BRAF, EGFR, ETV6, FGFR2, FGFR3, MET, NTRK1, RET and ROS1. SNV and Indels: AKT1, ARAF, ARID2, B2M, BCL2, BCOR, CARD11, CBFB, CBL, CCND1, CD79B, CDH1, CIC, CREBBP, CTCF, CTNNB1, DICER1, DIS3, EIF1AX, EP300, ERBB2, ERBB3, ESR1, EZH2, FGFR1, FGFR4, FLT3, FOXA1, FOXO1, FOXP1, FUBP1, GNA11, GNAQ, GNAS, H3F3A, HRAS, IDH1, IDH2, IKZF1, INPPL1, JAK1, JAK2, KIT, KNSTRN, MAP2K1, MAP2K2, MAPK1, MAX, MED12, MSH3, MTOR, MYC, MYCN, MYD88, MYOD1, NFE2L2, NOTCH1, NPM1, NRAS, NTRK2, NTRK3, NUP93, PAK5, PDGFRA, PHF6, PIK3CA, PIK3CB, PIK3R1, PIK3R2, PIM1, POLE, POT1, PPP2R1A, PPP6C, PRKCI, PTPN11, RAC1, RAD54L, RAF1, RHOA, RIT1, RRAS2, RXRA, SETD2, SF3B1, SMAD3, SMARCA4, SMARCB1, SOS1, SRSF2, STAT3, STK19, TCF7L2, TGFBR1, TGFBR2, TP63, U2AF1, and XPO1. SNV and Indels as well as Promoter: TERT | ||||
| Routine Turn Around Time: | 3 weeks | ||||
| Testing Schedule: | Weekly | ||||
| Performing Site: | OncoHelix Hematology Translational Lab (HTL) Attention: Cindy Miskolczi HMRB 336, 3330 Hospital Drive NW Calgary, Alberta T2N 4N1 | ||||
| Contact Comments: | Phone: (403) 220-7671 or (403) 210-3935 Email: Precision.Diagnostics@oncohelix.org or htl@ucalgary.ca | ||||
| Last Updated On: | Monday, January 20, 2025 | ||||
| Registered Trademark Comments: | STRECK Cell-Free DNA BCT® is a registred trademark of Streck,Inc. | ||||
